Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas

Immunotherapy

Volumn 6, Issue 11, 2014, Pages 1187-1206

  Remer, Marcus ^a   Al Shamkhani, Aymen ^a   Glennie, Martin ^a   Johnson, Peter ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

ADCC; ATL; CCR4; CTCL; defucosylated Fc region; FOXP3; glyco engineering; PTCL; Treg cell

Indexed keywords

ALEMTUZUMAB; ALISERTIB; ALPHA INTERFERON; ARSENIC TRIOXIDE; BASILIXIMAB; BELINOSTAT; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CYTOTOXIC AGENT; DENILEUKIN DIFTITOX; FORODESINE; HISTONE DEACETYLASE INHIBITOR; IMMUNOTOXIN LMB2; LENALIDOMIDE; LUMILIXIMAB; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; PANOBINOSTAT; PRALATREXATE; RETINOIC ACID; RITUXIMAB; ROMIDEPSIN; SIPLIZUMAB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VORINOSTAT; ZANOLIMUMAB; CCR4 PROTEIN, HUMAN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE OVEREXPRESSION; HELPER CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SKIN DEFECT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; T CELL LEUKEMIA; T CELL LYMPHOMA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUMOR IMMUNITY; ADULT; ANIMAL; GLYCOSYLATION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, T-CELL; METABOLISM; PROCEDURES; PROTEIN ENGINEERING;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CLINICAL TRIALS AS TOPIC; GLYCOSYLATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, T-CELL; PROTEIN ENGINEERING; RECEPTORS, CCR4; T-LYMPHOCYTES, REGULATORY;

EID: 84919792096     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.94     Document Type: Article

References (100)

1. Arisawa K, Soda M, Endo S, et al. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non- Hodgkin lymphoma incidence in southwestern Japan. Int. J. Cancer 85(3), 319-324 (2000
2. Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- And lymphoma-Type adult T-cell leukemia/lymphoma. J. Clin. Oncol. 30(14), 1635-1640 (2012
3. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J. Clin. Oncol. 25(34), 5458-5464 (2007
4. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. 9(10 Pt 1), 3625-3634 (2003
5. Yoshie O. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-Transformed T cells. Blood 99(5), 1505-1511 (2002
6. Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin. Cancer Res. 10(22), 7529-7539 (2004
7. Jones D, O'hara C, Kraus MD, et al. Expression pattern of T-cell-Associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96(2), 685-690 (2000
8. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J. Invest. Dermatol. 119(6), 1405-1410 (2002
9. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin. Cancer Res. 10(16), 5494-5500 (2004
10. Yano H, Ishida T, Inagaki A, et al. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin. Cancer Res. 13(21), 6494-6500 (2007
11. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64(6), 2127-2133 (2004
12. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 97(11), 1139-1146 (2006
13. Yano H, Ishida T, Imada K, et al. Augmentation of antitumor activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br. J. Hematol. 140(5), 586-589 (2008
14. Ito A, Ishida T, Utsunomiya A, et al. Defucosylated anti- CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J. Immunol. 183(7), 4782-4791 (2009
15. Ito A, Ishida T, Yano H, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol. Immunother. 58(8), 1195-1206 (2009
16. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-Type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl Acad. Sci. USA 110(44), 17945-17950 (2013
17. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen Density. Clin. Cancer Res. 11(6), 2327-2336 (2005
18. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28(9), 1591-1598 (2010
19. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter Phase II study. J. Clin. Oncol. 30(8), 837-842 (2012
20. Duvic M, Pinter-Brown L, Foss F, Al. E. Results of a Phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Presented at: The 52nd Annual Meeting of the American Society of Hematology. Orlando, USA; 4-7 December 2010 (Abstract 962
21. Ogura M, Ishida T, Hatake K, et al. Multicenter Phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J. Clin. Oncol. 32(11), 1157-1163 (2014
22. Sawada Y, Hino R, Hama K, et al. Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma. Blood 117(15), 3961-3967 (2011
23. Foss FM, Aquino SL, Ferry JA. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure. N. Engl. J. Med. 348(13), 1267-1275 (2003
24. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 50(3), 481-492 (1977
25. Matutes E. Adult T-cell leukaemia/lymphoma. J. Clin. Pathol. 60(12), 1373-1377 (2007
26. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J. Clin. Oncol. 26(25), 4124-4130 (2008
27. Zain JM, O'Connor O. Targeted treatment and new agents in peripheral T-cell lymphoma. Int. J. Hematol. 92(1), 33-44 (2010
28. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105(10), 3768-3785 (2005
29. Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur. J. Cancer 49(13), 2859-2868 (2013
30. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4(7), 540-550 (2004
31. Imai T, Chantry D, Raport CJ, et al. Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J. Biol. Chem. 273(3), 1764-1768 (1998
32. Vermeer MH, Dukers DF, Ten Berge RL, et al. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease. Mod. Pathol. 15(8), 838-844 (2002
33. Katou F, Ohtani H, Nakayama T, et al. Macrophage-derived chemokine (MDC/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue. Am. J. Pathol. 158(4), 1263-1270 (2001
34. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194(6), 847-853 (2001
35. Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int. Immunol. 11(1), 81-88 (1999
36. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004
37. Baatar D, Olkhanud P, Sumitomo K, Taub D, Gress R, Biragyn A. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J. Immunol. 178(8), 4891-4900 (2007
38. Inngjerdingen M, Damaj B, Maghazachi AA. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. J. Immunol. 164(8), 4048-4054 (2000
39. Power CA, Meyer A, Nemeth K, et al. Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J. Biol. Chem. 270(33), 19495-19500 (1995
40. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 96(13), 4046-4054 (2000
41. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int. Immunol. 16(11), 1643-1656 (2004
42. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187(1), 129-134 (1998
43. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: Chemokines in control of T cell traffic. Nat. Immunol. 9(9), 970-980 (2008
44. Sundrud MS, Grill SM, Ni D, et al. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J. Immunol. 171(7), 3542-3549 (2003
45. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 357(9255), 539-545 (2001
46. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654-2666 (2005
47. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003
48. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150(5), 1723-1734 (1997
49. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011
50. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005
51. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163(10), 5211-5218 (1999
52. Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-Transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61(24), 8643-8646 (2001
53. Karube K, Ohshima K, Tsuchiya T, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br. J. Hematol. 126(1), 81-84 (2004
54. Bonzheim I, Geissinger E, Tinguely M, et al. Evaluation of FoxP3 expression in peripheral T-cell lymphoma. Am. J. Clin. Pathol. 130(4), 613-619 (2008
55. Karube K, Aoki R, Sugita Y, et al. The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod. Pathol. 21(5), 617-625 (2008
56. Roncador G, Garcia JF, Garcia JF, et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. Leukemia 19(12), 2247-2253 (2005
57. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N. Engl. J. Med. 350(19), 1978-1988 (2004
58. Ohshima K, Karube K, Kawano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: Analysis of prognosis. Int. J. Oncol. 25(3), 605-613 (2004
59. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-Type adult T-cell leukemia/lymphoma. Clin. Cancer Res. 15(1), 30-38 (2009
60. Ishida T, Ueda R. Immunopathogenesis of Lymphoma: Focus on CCR4. Cancer Sci. 102(1), 44-50 (2011
61. Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 102(12), 4059-4066 (2003
62. Chang DK, Sui J, Geng S, et al. Humanization of an anti- CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol. Cancer Ther. 11(11), 2451-2461 (2012
63. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 113(26), 6528-6532 (2009
64. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. 5(2), 130-134 (2004
65. Maeda Y, Yamaguchi T, Hijikata Y, et al. Clinical efficacy of all-Trans retinoic acid for treating adult T cell leukemia. J. Cancer Res. Clin. Oncol. 134(6), 673-677 (2008
66. Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood 102(1), 284-288 (2003
67. Mone A, Puhalla S, Whitman S, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}- refractory adult T-cell leukemia. Blood 106(10), 3380-3382 (2005
68. Moura IC, Lepelletier Y, Arnulf B, et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103(5), 1838-1845 (2004
69. Callens C, Moura IC, Lepelletier Y, et al. Recent advances in adult T-cell leukemia therapy: Focus on a new anti-Transferrin receptor monoclonal antibody. Leukemia 22(1), 42-48 (2008
70. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J. Clin. Oncol. 27(3), 453-459 (2009
71. NCCN Clinical Practice guideline in oncology. Peripheral T-cell lymphoma. Version 1.2014;87-93. www.nccn.org/professionals/physician-gls/pdf/nhl.pdf
72. Dunleavy K, Piekarz RL, Zain J, et al. New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies. Clin. Cancer Res. 16(23), 5608-5617 (2010
73. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22), 5827-5834 (2011
74. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6), 631-636 (2012
75. O'connor O MT, Savage K, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. J. Clin. Oncol. 31(Suppl 15), Abstract 8507 (2013
76. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN- 35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a Phase II study. J. Clin. Oncol. 30(18), 2190-2196 (2012
77. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath- 1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7), 2316-2323 (2007
78. Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: A Phase II study. Cancer Chemother. Pharmacol. 60(1), 129-134 (2007
79. Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin Diftitox for relapsed/refractory T-cell non- Hodgkin lymphoma. Br. J. Hematol. 136(3), 439-447 (2007
80. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- And T-cell non-Hodgkin lymphomas. J. Clin. Oncol. 32(1), 44-50 (2014
81. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3), 754-758 (2002
82. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10(17), 5650-5655 (2004
83. Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin. Cancer Res. 16(5), 1520-1531 (2010
84. Ishida T, Ishii T, Inagaki A, et al. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma. Leukemia 20(12), 2162-2168 (2006
85. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-Acetylglucosamine of human IgG1 complex-Type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278(5), 3466-3473 (2003
86. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66(11), 5716-5722 (2006
87. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 100(9), 1566-1572 (2009
88. Suzuki R. Dosing of a Phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28(23), e404-e405; author reply e406 (2010
89. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002
90. Jo T, Ishida T, Takemoto S, et al. Randomized Phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL). J. Clin. Oncol. 31(Suppl 15), Abstract 8506 (2013
91. Ishida T, Ito A, Sato F, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia /lymphoma. Cancer Sci. 104(5), 647-650 (2013
92. Hodi FS, O'Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
93. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. mFOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112(13), 4953-4960 (2008
94. Kato K, Miyamoto T, Numata A, et al. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma. Int. J. Hematol. 97(3), 430-432 (2013
95. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114(5), 1209-1215 (2004
96. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens- Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14(12), 1343-1350 (2008
97. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: Timing of the dysfunction is associated with the pathological phenotype and outcome. J. Immunol. 182(12), 8071-8079 (2009
98. Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S. Prevention of toxic epidermal necrolysis by regulatory T cells. Eur. J. Immunol. 35(6), 1722-1730 (2005
99. Yano H, Ishida T, Inagaki A, et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int. J. Cancer 120(9), 2052-2057 (2007
100. Beck A, Reichert JM. Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 4(4), 419-425 (2012